Sichuan Biokin Pharma Plans IPO on STAR Board to Raise RMB 1.422 Billion
China-based Sichuan Biokin Pharmaceutical Co., Ltd is set to conduct an initial public offering (IPO)...
IPO
Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion
Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial...
Aier Eye Hospital Group Plans IPO on ChiNext Board
China-based ophthalmic medical services provider Aier Eye Hospital Group Co., Ltd (SHE: 300015) is set...
Suzhou Novoprotein Lists on Shanghai’s STAR Market for R&D Expansion
Suzhou Novoprotein Scientific Co., Ltd, a China-based provider of protein technology and application solutions, has...
Jenscare Scientific Set for IPO to Fund Structural Heart Disease Solutions
Jenscare Scientific Co., Ltd., a structural heart disease intervention device maker based in Ningbo, is...
InnoCare Pharma’s IPO Raises $411M for Drug R&D and Platform Upgrade
China-based InnoCare Pharma (HKG: 9969) has completed an initial public offering (IPO) of 265 million...
AIM Vaccine Plans IPO to Fund Vaccine R&D and Pipeline Expansion
China-based AIM Vaccine Co., Ltd plans to make an initial public offering (IPO) of 9.71...
Joincare Pharmaceuticals Prices GDRs on SIX Swiss Exchange
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has priced its Global Depository Receipts...
Apollomics Set to Merge with Maxpro Capital for Nasdaq Listing
Sino-US biotech Apollomics Inc. has revealed plans to merge with the special purpose acquisition company...
Bide Pharmatech Set for IPO on Shanghai’s STAR Market
Shanghai-based Bide Pharmatech Co., Ltd, a specialist in drug building blocks, is set to make...
Bio-Heart Plans STAR Board IPO After Hong Kong Debut to Advance Cardiovascular Therapies
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese innovator in interventional cardiovascular...
InnoCare Pharma Files for STAR Market IPO to Raise RMB 4B for Drug R&D
China-based InnoCare Pharma (HKG: 9969) has filed for an initial public offering (IPO) on the...
Biocytogen Pharmaceuticals Makes HKSE Debut with USD 70 Million IPO
Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has completed an initial public...
MingMed Biotech’s Hong Kong IPO Signals Push for First-in-Class Drugs
Guangzhou-based MingMed Biotech has officially made an initial public offering (IPO) to the Hong Kong...
Medlander Medical Technology’s IPO Raises RMB 1 billion on Shanghai’s STAR Board
Medlander Medical Technology Inc., a leading Chinese manufacturer of pelvic floor rehabilitation equipment, has completed...
United Imaging Healthcare’s STAR Listing Raises USD1.85 Billion
Shanghai-based United Imaging Healthcare (UIH) has completed an initial public offering (IPO) of 100 million...
Sinotherapeutics Inc. to Raise RMB600m via STAR Board IPO for Generic Drug Expansion
Sinotherapeutics Inc., a Shanghai-based generic drug developer, is set to make an initial public offering...
MicuRx Pharmaceuticals Completes RMB1.06B IPO for Antibacterial Drug Development
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals has officially made an initial public offering (IPO) of...
HeNan Genuine Biotech Files for IPO to Fund Azvudine Commercialization
China-based HeNan Genuine Biotech Co., Ltd has filed for an initial public offering (IPO) with...
3D Medicines Files IPO Prospectus for Hong Kong Listing
China-based oncology specialist 3D Medicines has published its initial public offering (IPO) prospectus with the...